The Analyst Report That Took Three Weeks Should Have Taken Three Hours — Here’s the Bottleneck
A comprehensive freedom-to-operate analysis for a pharmaceutical asset takes four to twelve weeks and costs $50,000 to $200,000 in legal […]
Why “We’ll Catch It in the Quarterly Review” Is How Companies Miss NCE-1 Dates Every Year
On September 9, 2026, Bristol-Myers Squibb’s five-year new chemical entity (NCE) exclusivity for Sotyktu (deucravacitinib) reaches its four-year mark. That
Stop Searching Patents. Start Asking Them Questions.
On October 8, 2025, the U.S. Patent and Trademark Office quietly admitted something the patent search industry had been saying
Stop Searching Patents. Start Asking Them Questions. Read Post »
Your Competitive Intelligence Team Is Still Reading PACER by Hand. Here Is the Cost in Reaction Time.
The Short Answer A pharmaceutical patent lawsuit becomes public the moment it is entered on a federal docket. Nobody has
The Three-Clock Problem: Why Patent Expiration Dates Don’t Predict Generic Launch Dates
Eight of Teva’s nine Copaxone patents expired in May 2014. The first FDA-approved generic, Sandoz’s Glatopa, didn’t reach a pharmacy
The Three-Clock Problem: Why Patent Expiration Dates Don’t Predict Generic Launch Dates Read Post »
The Patent Cliff Is a Myth. What Actually Happens Is a Patent Staircase, and Most Models Miss the Steps
In March 2022, the first generic version of Bristol Myers Squibb’s cancer drug Revlimid reached U.S. pharmacies. It launched at
The Blockbuster’s Real Patent Is the Weak One Nobody Challenged
GSK’s Advair lost its core patent in 2010. Fourteen years later the inhaler was still bringing in £863 million —
The Blockbuster’s Real Patent Is the Weak One Nobody Challenged Read Post »
Strong IP Doesn’t Win in Court. Enforceable IP Does.
In May 2023, the Supreme Court unanimously threw out two Amgen patents that, on their face, covered every antibody that
Strong IP Doesn’t Win in Court. Enforceable IP Does. Read Post »
Stop Calling It “Loss of Exclusivity” — For Most Drugs, It’s Loss of Pricing Power, Not Loss of Revenue
Nine months after Humira lost U.S. exclusivity, biosimilars held four percent of the market. AbbVie’s Humira still controlled ninety-six percent
